ClinicalTrials.gg
CompletedNCT01262677Updated Jan 25, 2021Results posted

Once-A-Day Pregabalin For Partial Seizures

A Phase 3 interventional study of pregabalin and pregabalin in Partial Seizures and Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 82 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pregabalin in Seizures — none open to participants now, none under way, none of them phase 3. Pregabalin · Seizures.

Enrollment
5th of 10
325 · median 276
Started
2011
the only one that year
Phase 3
7 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
9 of 10
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 10 studies testing pregabalin in Seizures, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 9th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 10 studies testing pregabalin in Seizures is open now. The open studies under Seizures, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing pregabalin in Seizures as a file.
02

Study summary

Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.

03

Conditions studied

  • Partial Seizures
  • Epilepsies, Partial

Keywords

  • Partial epilepsy
  • partial seizures
  • epilepsy
  • seizures
  • adjunctive therapy
  • intervention
  • controlled-release
  • placebo-controlled
  • seizure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of epilepsy with partial onset seizures (seizures may be simple or complex, with or without evolution into a bilateral, convulsive seizure)
  • Currently taking 1 to 3 anti-epilepsy medicines (AEDs) at stable dosages, and who have taken at least 2 prior (or ongoing) AEDs

Exclusion criteria

Exclusion Criteria:

  • Primary generalized seizures (for example, absence, myoclonic seizures or Lennox-Gastaut Syndrome)
  • Status epilepticus within one year prior to screening
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    pregabalin CR 330 mg

    Drug: pregabalin

  • Experimental
    pregabalin CR 165 mg

    Drug: pregabalin

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days

  • Controlled Release Tablets, 165 mg, once per day (QD) for 11 days

  • Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)

  • Controlled Release Tablets, 165 mg, once per day (QD) for 7 days

  • Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days

  • Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)

  • Drugplacebo

    matched to the active drug

06

What researchers measure

Primary outcomes

  1. Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

    Time frame: Week 0 to Week 14

Secondary outcomes

  1. Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Participants who had a ≥50% reduction in the 28-day partial seizure rate from baseline were defined as a responder, otherwise they were default as a non-responder.

    Time frame: Week 0 to Week 14

  2. Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

    Time frame: Week 0 to Week 14

  3. Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.

    Time frame: Week 0 to Week 14

  4. Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

    Time frame: Week 2 to Week 14

  5. Percentage of Participants With ≥50% Reduction in 28-day SGTC Seizure Rate From Baseline During the Double-blind Treatment Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.

    Time frame: Week 0 to Week 14

  6. Loge 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Maintenance Phase

    Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

    Time frame: Week 2 to Week 14

  7. Change From Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at Week 14

    HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 14

  8. Change From Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at Week 14

    HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 14

  9. Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  10. Change From Baseline in MOS-SS - Snoring Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  11. Change From Baseline in MOS-SS - Awaken Short of Breath or With Headache Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  12. Change From Baseline in MOS-SS - Quantity of Sleep (Hours) at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  13. Change From Baseline in MOS-SS - Sleep Adequacy Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  14. Change From Baseline in MOS-SS - Sleep Somnolence Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  15. Change From Baseline in MOS-SS - Sleep Problems Index I Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  16. Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Problems Index II Score at Week 14

    Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

    Time frame: Baseline, Week 14

  17. Percent of Participants Reporting Optimal Sleep on the MOS-SS - Optimal Sleep Subscale

    Optimal sleep was considered between 7 to 8 hours of average sleep per night inclusive, while average sleep less than or greater than the 7 to 8 hour of average sleep per night was non-optimal.

    Time frame: Week 14

  18. Benefit, Satisfaction, and Willingness to Continue Measure (BSW): Benefit From Treatment Question

    The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.

    Time frame: Week 14

  19. BSW: Satisfaction From Treatment Question

    The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.

    Time frame: Week 14

  20. BSW: Willingness to Continue Question

    The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.

    Time frame: Week 14

  21. Percentage of Participants With New or Intensified Physical Examination Findings During the Double-blind Treatment Phase

    Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal (abdominal rigidity and tenderness), an extremities (e.g. edema). Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.

    Time frame: Day 1 to Week 15

  22. Percentage of Participants With New or Intensified Neurological Examination Findings During the Double-blind Treatment Phase

    Neurological examinations included level of consciousness, mental status, cranial nerve assessment, muscle strength, reflexes, pin prick and vibratory sensation (the latter using a 128-Hz tuning fork), coordination and gait.

    Time frame: Day 1 to Week 15

  23. Percentage of Participants With Self-injurious or Suicidal Ideation or Behavior on Columbia Classification Algorithm of Suicide Assessment (C-CASA)

    C-CASA is described as a standardized suicidal rating system. The C-CASA has eight categories (4 suicidal events: completed suicide, suicide attempt, preparatory act toward imminent suicidal behavior (PAISB), and suicidal ideation; 2 nonsuicidal events: self-injurious behavior, no suicidal intent (SIB-NSI) and other no deliberate self-harm, and 2 indeterminate or potentially suicidal events: self-injurious behavior, suicidal intent unknown and not enough information) that distinguish suicidal events from nonsuicidal events and indeterminate or potentially suicidal events.

    Time frame: Week -8 (Screening), Week 0 (Baseline), and Week 14 (double-blind treatment phase)

  24. Percentage of Participants With a Relevant Increase in Sitting Blood Pressure (BP) From Baseline During the Double-blind Treatment Phase

    Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest (ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal(abdominal rigidity and tenderness), an extremities (e.g. edema).

    Time frame: Day 1 to Week 15

  25. Percentage of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 450 ms

    The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) were calculated.

    Time frame: Week 15

  26. Percentage of Participants With Relevant ECG Interval-increases From Baseline During the Double-blind Treatment Phase

    The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. 25/50% represents ≥25% or ≥50% increase over baseline respectively, based on cut points. Cut points are 100 ms for QRS and 200 ms for PR.

    Time frame: Week 15

  27. Percentage of Participants With Laboratory Test Abnormalities During the Study

    Laboratory samples in hematology, chemistry, and urinalysis were analyzed by a cental laboratory. Any laboratory value that was identified as clinically significant was reported as an AE. LLN: Lower limit of normal, ULN: Uper limit of normal, RBC: Red Blood Cell, WBC: White Blood Cell, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, BUN: Blood Urea Nitrogen

    Time frame: Day 1 to Week 15

07

Results

Posted Jun 6, 2018

Participant flow

This was a multicenter, multinational study and included four standard phases: an 8-week baseline observation phase, a 2-week dose escalation phase, a 12-week fixed-dose maintenance phase, and a 1-week taper phase.

Participant flow — Overall Study
MilestonePregabalin 165 mgPregabalin 330 mgPlacebo
Started100113110
Completed919898
Not completed91512
Withdrew: Does not meet entrance criteria020
Withdrew: Insufficient clinical response001
Withdrew: Lost to follow-up102
Withdrew: No longer willing to participate332
Withdrew: Reason not provided213
Withdrew: Protocol violation011
Withdrew: Adverse event (ae) related to study drug383

Outcome measures

PrimaryLog Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

Time frame:
Week 0 to Week 14
Reported as:
Mean · ln (seizures per 28 days)
Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase
ln (seizures per 28 days)Pregabalin 165 mgPregabalin 330 mgPlacebo
Baseline2.24 ± 0.7572.33 ± 0.8732.32 ± 0.910
Week 141.84 ± 1.0031.80 ± 1.0301.93 ± 1.132
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANCOVA · p = 0.9076 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Mean difference: -0.99 · 95% CI -16.28 to 17.11Value is percent reduction in seizures relative to placebo.
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.0907 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Mean difference: -13.05 · 95% CI -26.07 to 2.25Value is percent reduction in seizures relative to placebo.
SecondaryPercentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Participants who had a ≥50% reduction in the 28-day partial seizure rate from baseline were defined as a responder, otherwise they were default as a non-responder.

Time frame:
Week 0 to Week 14
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Responder37.845.935.8
Non-responder62.254.164.2
Statistical analysis
  • Pregabalin 165 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.752 (Statistical testing was done at alpha = 0.05 level, two-sided.)
  • Pregabalin 330 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.125 (Statistical testing was done at alpha = 0.05 level, two-sided.)
SecondaryPercentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

Time frame:
Week 0 to Week 14
Reported as:
Least squares mean · ln (seizures per 28 days)
Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase
ln (seizures per 28 days)Pregabalin 165 mgPregabalin 330 mgPlacebo
Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase-15.00 ± 11.668-31.54 ± 10.772-5.70 ± 10.918
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANCOVA · p = 0.5404 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -9.30 · 95% CI -39.16 to 20.56Value is percent reduction in seizures relative to placebo.
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.0786 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -25.84 · 95% CI -54.64 to 2.97Value is percent reduction in seizures relative to placebo.
SecondaryFrequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.

Time frame:
Week 0 to Week 14
Reported as:
Mean · seizures per 28 days
Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase
seizures per 28 daysPregabalin 165 mgPregabalin 330 mgPlacebo
Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase3.99 ± 8.6674.43 ± 14.7367.51 ± 24.979
Statistical analysis
  • Pregabalin 165 mg vs Placebo · Generalized linear model (GLM) · p = 0.6073 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -0.11 · 95% CI -0.53 to 0.31
  • Pregabalin 330 mg vs Placebo · GLM · p = 0.4109 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -0.16 · 95% CI -0.53 to 0.22
SecondaryLog Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

Time frame:
Week 2 to Week 14
Reported as:
Least squares mean · ln (seizures per 28 days)
Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase
ln (seizures per 28 days)Pregabalin 165 mgPregabalin 330 mgPlacebo
Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase0.46 ± 0.0490.48 ± 0.0450.48 ± 0.046
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANCOVA · p = 0.8268 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -1.38 · 95% CI -12.97 to 11.75Value is percent reduction in seizures relative to placebo.
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.9024 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.75 · 95% CI -10.69 to 13.66Value is percent reduction in seizures relative to placebo.
SecondaryPercentage of Participants With ≥50% Reduction in 28-day SGTC Seizure Rate From Baseline During the Double-blind Treatment Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.

Time frame:
Week 0 to Week 14
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction in 28-day SGTC Seizure Rate From Baseline During the Double-blind Treatment Phase
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Percentage of Participants With ≥50% Reduction in 28-day SGTC Seizure Rate From Baseline During the Double-blind Treatment Phase1.01.91.9
Statistical analysis
  • Pregabalin 165 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.670 (Statistical testing was done at alpha = 0.05 level, two-sided.)
  • Pregabalin 330 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.927 (Statistical testing was done at alpha = 0.05 level, two-sided.)
SecondaryLoge 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Maintenance Phase

Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.

Time frame:
Week 2 to Week 14
Reported as:
Least squares mean · ln(28-day seizure rate)
Loge 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Maintenance Phase
ln(28-day seizure rate)Pregabalin 165 mgPregabalin 330 mgPlacebo
Loge 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Maintenance Phase1.91 ± 0.0701.77 ± 0.0641.88 ± 0.065
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANCOVA · p = 0.8034 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Ls mean difference: 2.28 · 95% CI -14.37 to 22.15Value is percent reduction in seizures relative to placebo.
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.1905 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Ls mean difference: -10.78 · 95% CI -24.81 to 5.87Value is percent reduction in seizures relative to placebo.
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at Week 14

HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at Week 14-0.8 ± 3.34-0.4 ± 3.19-0.5 ± 3.13
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANCOVA · p = 0.4650 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Ls mean difference: -0.3 · 95% CI -1.1 to 0.5
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.9692 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Ls mean difference: 0.0 · 95% CI -0.8 to 0.8
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at Week 14

HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at Week 14-0.5 ± 3.16-0.8 ± 3.49-0.1 ± 3.17
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANCOVA · p = 0.2693 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Ls mean difference: -0.5 · 95% CI -1.3 to 0.4
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.1893 (Statistical testing was done at 95% confidence intervals, two-sided, least square means and their standard errors.) · Ls mean difference: -0.5 · 95% CI -1.4 to 0.3
SecondaryChange From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Score at Week 14-3.9 ± 19.89-1.5 ± 17.93-1.9 ± 14.10
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.7347 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -0.8 · 95% CI -5.2 to 3.6
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.8971 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.3 · 95% CI -4.0 to 4.6
SecondaryChange From Baseline in MOS-SS - Snoring Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in MOS-SS - Snoring Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in MOS-SS - Snoring Score at Week 14-3.5 ± 25.445.4 ± 26.00-0.6 ± 22.71
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.3972 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -2.7 · 95% CI -9.1 to 3.6
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.0319 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 6.7 · 95% CI 0.6 to 12.9
SecondaryChange From Baseline in MOS-SS - Awaken Short of Breath or With Headache Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in MOS-SS - Awaken Short of Breath or With Headache Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in MOS-SS - Awaken Short of Breath or With Headache Score at Week 140.2 ± 20.751.0 ± 24.48-0.8 ± 18.96
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.7708 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.8 · 95% CI -4.4 to 5.9
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.3560 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 2.4 · 95% CI -2.7 to 7.4
SecondaryChange From Baseline in MOS-SS - Quantity of Sleep (Hours) at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · hours
Change From Baseline in MOS-SS - Quantity of Sleep (Hours) at Week 14
hoursPregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in MOS-SS - Quantity of Sleep (Hours) at Week 140.2 ± 1.31-0.1 ± 1.18-0.1 ± 1.25
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.1129 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.2 · 95% CI -0.1 to 0.5
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.9388 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.0 · 95% CI -0.3 to 0.3
SecondaryChange From Baseline in MOS-SS - Sleep Adequacy Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in MOS-SS - Sleep Adequacy Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in MOS-SS - Sleep Adequacy Score at Week 142.3 ± 31.14-1.7 ± 31.44-1.5 ± 24.55
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.9053 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -0.4 · 95% CI -7.5 to 6.6
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.6371 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -1.6 · 95% CI -8.5 to 5.2
SecondaryChange From Baseline in MOS-SS - Sleep Somnolence Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in MOS-SS - Sleep Somnolence Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in MOS-SS - Sleep Somnolence Score at Week 14-0.5 ± 17.295.2 ± 19.425.0 ± 18.72
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.0119 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -6.4 · 95% CI -11.4 to -1.4
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.9909 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.0 · 95% CI -4.9 to 4.8
SecondaryChange From Baseline in MOS-SS - Sleep Problems Index I Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in MOS-SS - Sleep Problems Index I Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in MOS-SS - Sleep Problems Index I Score at Week 14-2.2 ± 16.910.4 ± 16.430.3 ± 12.62
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.5903 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -1.1 · 95% CI -5.0 to 2.8
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.7126 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.7 · 95% CI -3.1 to 4.5
SecondaryChange From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Problems Index II Score at Week 14

Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame:
Baseline, Week 14
Reported as:
Mean · units on a scale
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Problems Index II Score at Week 14
units on a scalePregabalin 165 mgPregabalin 330 mgPlacebo
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Problems Index II Score at Week 14-2.4 ± 15.620.7 ± 14.530.7 ± 11.30
Statistical analysis
  • Pregabalin 165 mg vs Placebo · ANOVA · p = 0.2431 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: -2.1 · 95% CI -5.8 to 1.5
  • Pregabalin 330 mg vs Placebo · ANCOVA · p = 0.8654 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Ls mean difference: 0.3 · 95% CI -3.2 to 3.8
SecondaryPercent of Participants Reporting Optimal Sleep on the MOS-SS - Optimal Sleep Subscale

Optimal sleep was considered between 7 to 8 hours of average sleep per night inclusive, while average sleep less than or greater than the 7 to 8 hour of average sleep per night was non-optimal.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Percent of Participants Reporting Optimal Sleep on the MOS-SS - Optimal Sleep Subscale
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Percent of Participants Reporting Optimal Sleep on the MOS-SS - Optimal Sleep Subscale67.760.260.2
Statistical analysis
  • Pregabalin 165 mg vs Placebo · Regression, Logistic · p = 0.3241 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Odds ratio (or): 1.36 · 95% CI 0.74 to 2.50
  • Pregabalin 330 mg vs Placebo · Regression, Logistic · p = 0.8932 (Statistical testing was done at alpha = 0.05 level, two-sided.) · Odds ratio (or): 0.96 · 95% CI 0.54 to 1.71
SecondaryBenefit, Satisfaction, and Willingness to Continue Measure (BSW): Benefit From Treatment Question

The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Benefit, Satisfaction, and Willingness to Continue Measure (BSW): Benefit From Treatment Question
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
No12.017.922.0
Little benefit31.023.233.0
Much benefit54.056.342.2
Not done2.01.81.8
Missing1.00.90.9
SecondaryBSW: Satisfaction From Treatment Question

The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.

Time frame:
Week 14
Reported as:
Number · percentage of participants
BSW: Satisfaction From Treatment Question
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
No13.017.923.9
Yes84.080.473.4
Missing3.01.82.8
SecondaryBSW: Willingness to Continue Question

The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.

Time frame:
Week 14
Reported as:
Number · percentage of participants
BSW: Willingness to Continue Question
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
No18.022.326.6
Yes79.075.970.6
Missing3.01.82.8
SecondaryPercentage of Participants With New or Intensified Physical Examination Findings During the Double-blind Treatment Phase

Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal (abdominal rigidity and tenderness), an extremities (e.g. edema). Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.

Time frame:
Day 1 to Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With New or Intensified Physical Examination Findings During the Double-blind Treatment Phase
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
General1.02.70.0
Skin2.06.24.5
Head1.01.80.0
Ears3.01.80.9
Eyes1.02.73.6
Nose0.00.01.8
Throat0.00.01.8
Lungs0.00.00.0
Heart1.00.00.0
Abdomen0.00.00.0
Extremities2.02.71.8
Other14.07.110.9
SecondaryPercentage of Participants With New or Intensified Neurological Examination Findings During the Double-blind Treatment Phase

Neurological examinations included level of consciousness, mental status, cranial nerve assessment, muscle strength, reflexes, pin prick and vibratory sensation (the latter using a 128-Hz tuning fork), coordination and gait.

Time frame:
Day 1 to Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With New or Intensified Neurological Examination Findings During the Double-blind Treatment Phase
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
None79.078.868.2
Any21.021.231.8
Coordination1.01.81.8
Cranial nerve function0.00.90.0
Cranial nerve II0.00.00.0
Cranial nerve III0.00.01.8
Cranial nerve V0.00.00.0
Cranial nerve VII1.00.00.9
Cranial nerve VIII0.00.90.0
Cranial nerve XI0.00.00.0
Deep tendon reflexes3.01.82.7
Gait and station0.00.00.9
Level of consciousness0.00.00.9
Mental state1.01.81.8
Motor function1.02.73.6
Muscle strength2.00.01.9
Pain sensation0.00.01.9
Reflexes1.00.91.9
Vibration11.110.812.0
SecondaryPercentage of Participants With Self-injurious or Suicidal Ideation or Behavior on Columbia Classification Algorithm of Suicide Assessment (C-CASA)

C-CASA is described as a standardized suicidal rating system. The C-CASA has eight categories (4 suicidal events: completed suicide, suicide attempt, preparatory act toward imminent suicidal behavior (PAISB), and suicidal ideation; 2 nonsuicidal events: self-injurious behavior, no suicidal intent (SIB-NSI) and other no deliberate self-harm, and 2 indeterminate or potentially suicidal events: self-injurious behavior, suicidal intent unknown and not enough information) that distinguish suicidal events from nonsuicidal events and indeterminate or potentially suicidal events.

Time frame:
Week -8 (Screening), Week 0 (Baseline), and Week 14 (double-blind treatment phase)
Reported as:
Number · percentage of participants
Percentage of Participants With Self-injurious or Suicidal Ideation or Behavior on Columbia Classification Algorithm of Suicide Assessment (C-CASA)
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Suicide attempt (Lifetime prior to Screening)2.01.85.5
PAISB (Lifetime prior to Screening)1.01.84.5
Suicidal ideation (Lifetime prior to Screening)11.010.614.5
SIB-NSI (Lifetime prior to Screening)1.00.90.9
Suicide attempts at Week 01.00.90.0
PAISB at Week 00.00.90.0
Suicidal ideation at Week 08.07.12.7
SIB-NSI at Week 01.00.00.0
Suicidal ideation at Week 144.02.71.8
SecondaryPercentage of Participants With a Relevant Increase in Sitting Blood Pressure (BP) From Baseline During the Double-blind Treatment Phase

Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest (ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal(abdominal rigidity and tenderness), an extremities (e.g. edema).

Time frame:
Day 1 to Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With a Relevant Increase in Sitting Blood Pressure (BP) From Baseline During the Double-blind Treatment Phase
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Maximum increase in systolic BP ≥30 mmHg1.01.80.9
Maximum increase in diastolic BP ≥20 mmHg5.15.52.8
SecondaryPercentage of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 450 ms

The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) were calculated.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 450 ms
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Maximum QTcB 450 - <4808.05.310.0
Maximum QTcB 480 - <5001.00.00.9
Maximum QTcB ≥5000.01.80.0
Maximum QTcF 450 - <4803.02.73.6
Maximum QTcF 480 - <5001.00.00.0
Maximum QTcF ≥5000.00.00.0
SecondaryPercentage of Participants With Relevant ECG Interval-increases From Baseline During the Double-blind Treatment Phase

The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. 25/50% represents ≥25% or ≥50% increase over baseline respectively, based on cut points. Cut points are 100 ms for QRS and 200 ms for PR.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With Relevant ECG Interval-increases From Baseline During the Double-blind Treatment Phase
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Max PR interval rise:%change≥25/50%1.11.02.1
Max QRS complex rise:%change≥25/50%1.11.91.0
Max. QTcB interval rise: 30≤x<605.41.93.1
Max. QTcB interval rise: ≥600.01.90.0
Max. QTcF interval rise: 30≤x<603.21.92.1
Max. QTcF interval rise: ≥600.00.00.0
SecondaryPercentage of Participants With Laboratory Test Abnormalities During the Study

Laboratory samples in hematology, chemistry, and urinalysis were analyzed by a cental laboratory. Any laboratory value that was identified as clinically significant was reported as an AE. LLN: Lower limit of normal, ULN: Uper limit of normal, RBC: Red Blood Cell, WBC: White Blood Cell, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, BUN: Blood Urea Nitrogen

Time frame:
Day 1 to Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With Laboratory Test Abnormalities During the Study
percentage of participantsPregabalin 165 mgPregabalin 330 mgPlacebo
Hemoglobin (HGB) <0.8xLLN ,1.00.90.9
Hematocrit (HCT) <0.8xLLN0.00.90.0
RBC Count <0.8xLLN0.00.00.0
Platelets <0.5xLLN0.00.00.0
Platelets >1.75xULN0.00.00.0
WBC Count <0.6xLLN0.00.90.0
White Blood Cell Count >1.5xULN0.00.00.0
Lymphocytes (absolute) <0.8xLLN4.20.91.9
Lymphocytes (absolute) >1.2xULN2.11.83.8
Lymphocytes (%) <0.8xLLN0.00.01.9
Lymphocytes (%) >1.2xULN1.00.00.9
Neutrophils (absolute) <0.8xLLN3.11.81.9
Neutrophils (absolute) >1.2xULN0.00.01.9
Neutrophils (%) <0.8xLLN1.00.00.0
Neutrophils (%) >1.2xULN0.00.00.0
Basophils (absolute) >1.2xULN0.00.00.0
Basophils (%) >1.2xULN0.00.00.0
Eosinophils (absolute) >1.2xULN3.13.71.9
Eosinophils (%) >1.2xULN6.34.63.8
Monocytes (absolute) >1.2xULN0.01.80.0
Monocytes (%) >1.2xULN1.00.00.0
Total Bilirubin >1.5xULN0.00.00.0
AST >3.0xULN0.00.00.0
ALT >3.0xULN0.00.00.0
Alkaline Phosphatase >3.0xULN0.00.00.0
Total Protein <0.8xLLN0.00.00.0
Total Protein >1.2xULN0.00.00.0
Albumin <0.8xLLN0.00.00.0
Albumin >1.2xULN0.00.00.0
BUN >1.3xULN0.00.00.0
Creatinine >1.3xULN0.00.00.0
Uric Acid >1.2xULN1.00.90.0
Sodium <0.95xLLN1.00.00.0
Sodium >1.05xULN0.00.00.0
Potassium <0.9xLLN2.00.00.0
Potassium >1.1xULN1.00.00.0
Chloride <0.9xLLN0.00.00.0
Chloride >1.1xULN0.00.00.0
Calcium <0.9xLLN0.00.00.0
Calcium >1.1xULN0.00.00.0
Glucose <0.6xLLN0.00.00.0
Glucose >1.5xULN0.00.90.0
Urine Specific Gravity <1.0030.01.91.0
Urine Specific Gravity >1.0301.11.94.8
Urine pH <4.50.00.00.0
Urine pH >81.11.91.9
Urine Glucose (qualitative) ≥10.00.90.0
Urine Ketones (qualitative) ≥12.11.91.9
Urine Protein (qualitative) ≥13.22.81.0
Urine Blood/Hgb (qualitative) ≥18.59.49.5
Urine Nitrite ≥111.75.713.3
Urine RBC ≥2013.30.09.5
Urine WBC ≥204.83.729.6

Adverse events

Collected over From the time the participant provided informed consent, which was obtained prior to the participant's participation in the study, through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 165 mg—5/100 (5%)14/100 (14%)
Pregabalin 330 mg—5/113 (4.4%)21/113 (18.6%)
Placebo—2/110 (1.8%)3/110 (2.7%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPregabalin 165 mgPregabalin 330 mgPlacebo
BronchitisInfections and infestations1/1000/1130/110
PneumoniaInfections and infestations1/1000/1130/110
Viral infectionInfections and infestations1/1000/1130/110
Complex partial seizuresNervous system disorders1/1000/1130/110
ConvulsionNervous system disorders1/1001/1131/110
EpilepsyNervous system disorders1/1000/1130/110
Grand mal convulsionNervous system disorders1/1000/1130/110
WoundInjury, poisoning and procedural complications0/1000/1131/110
Subcutaneous abscessInfections and infestations0/1001/1130/110
AtaxiaNervous system disorders0/1001/1130/110
Most frequent other events
Most frequent other events
EventPregabalin 165 mgPregabalin 330 mgPlacebo
DizzinessNervous system disorders11/10011/1132/110
Weight increasedInvestigations1/1007/1130/110
FatigueGeneral disorders3/1006/1131/110

Baseline characteristics

The safety analysis set included all randomized participants who took at least one dose of the study medication.

Age, Continuous
Age, Continuous(years)Pregabalin 165 mgPregabalin 330 mgPlaceboTotal
Mean37.88 ± 13.1039.58 ± 13.1538.72 ± 13.2538.76 ± 13.14
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 165 mgPregabalin 330 mgPlaceboTotal
Female535561169
Male475849154
08

Study locations

82 sites
  • Neurology Clinic, PC
    Northport, Alabama 35476, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Clinical Trials, Inc.
    Little Rock, Arkansas 72205, United States
  • Collaborative Neuroscience Network, Inc.
    Long Beach, California 90806, United States
  • Viking Clinic Research Center
    Murrieta, California 92562, United States
  • Viking Clinical Research Center
    Murrieta, California 92562, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • Viking Clinical Research Center
    Temecula, California 92591, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Optima Neurological Services, LLC
    Gainesville, Florida 32608, United States
  • Sleep Disorders Center of Georgia - Gainesville
    Gainesville, Georgia 30501, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • VCMA Comprehensive Epilepsy Center
    Wichita, Kansas 67214, United States
  • Via Christi Research
    Wichita, Kansas 67214, United States
  • Associates in Neurology, PSC
    Lexington, Kentucky 40513, United States
  • Mid Atlantic Headache Institute
    Pikesville, Maryland 21208, United States
  • Asheville Neurology Specialists, PA
    Asheville, North Carolina 28806, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Mark A. Fisher, M.D.- Private Practice
    Oklahoma City, Oklahoma 73112, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Veroniqe Sebastian, MD
    Oklahoma City, Oklahoma 73120, United States
  • Angelique Barreto, MD
    Oklahoma City, Oklahoma 73135, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Scott and White Healthcare-Office of Sponsored Research Administration
    Temple, Texas 76502, United States
  • Scott & White Healthcare
    Temple, Texas 76508, United States
  • Fundacion Argentina Contra las Enfermedades Neurologicas (FACENE)
    Ciudad Autonoma de Buenos Aires, C1117ABE, Argentina
  • Clinic of Neurology,Clinical Centar University Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • MBAL Puls AD, Nevrologichno otdelenie
    Blagoevgrad, 2700, Bulgaria
  • UMBAL Dr. Georgi Stranski, Vtora nevrologichna klinika
    Pleven, 5800, Bulgaria
  • DKTs Akta Medika, Konsultativen kabinet po Nevrologiya
    Sevlievo, 5400, Bulgaria
  • MBALNP Sveti Naum EAD, Klinika po nervni bolesti za paroksizmalnite sastoyaniya,
    Sofia, 1113, Bulgaria
  • Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie, Nevrologichno Otdelenie
    Sofia, 1202, Bulgaria
  • Litomyslská nemocnice, a.s.
    Litomysl, 570 14, Czechia
  • Fakultni Thomayerova nemocnice s poliklinikou,Neurologicka klinika IPVZ/FTNsP
    Praha 4, 140 59, Czechia
  • Neurologicka ambulance
    Praha 6, 160 00, Czechia
  • Epilepsie-Zentrum Bethel
    Bielefeld, 33617, Germany
  • Praxis fuer Neurologie und Psychiatrie, Psychotherapie
    Bielefeld, 33647, Germany
  • Klinik fuer Epileptologie, Universitaet Bonn
    Bonn, 53105, Germany
  • Neuro Consil GmbH
    Duesseldorf, 40212, Germany
  • Epilepsieklinik fuer Erwachsene Epilepsiezentrum Kork
    Kehl-Kork, 77694, Germany
  • Studienzentrum Dr. Stephan Arnold
    Muenchen, 80638, Germany
  • Pamela Youde Nethersole Eastern Hospital
    Hong Kong, Hong Kong
  • Department of Medicine, Queen Elizabeth Hospital
    Kowloon, 0, Hong Kong
  • Dr. Kennessey Albert Korhaz-Rendelointezet, Neurologiai Osztaly
    Balassagyarmat, 2660, Hungary
  • Synexus Magyarorszag Kft.
    Budapest, 1036, Hungary
  • Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Ideggyogyaszati Osztaly
    Budapest, 1145, Hungary
  • Szent Pantaleon Korhaz Nonprofit Kft., Idegosztaly
    Dunaujvaros, 2400, Hungary
  • Lalitha Super Specialities Hospital (P) Ltd.
    Guntur, Andhra Pradesh 522 001, India
  • Jagadguru Sri Shivathreeshwara Medical College and Hospital,
    Mysore, Karnataka 570004, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, Maharashtra 411 004, India
  • Sahyadri Clinical Research & Development Center,
    Pune, Maharashtra 411 004, India
  • KEM Hospital Research Centre
    Pune, Maharashtra 411 011, India
  • Sahyadri Speciality Hospital
    Pune, Maharashtra 411004, India
  • Poona Hospital and Research Centre Department of Neurology
    Pune, Maharashtra 411030, India
  • Vidyasagar Institute of Mental Health , Neuro& Allied Sciences,
    Nehru Nagar, NEW Delhi 110 065, India
  • Jabatan Neurosains, Pusat Pengajian Sains Perubatan, Universiti Sains Malaysia.
    Kubang Kerian, Kelantan 16150, Malaysia
  • Hospital Universiti Sains Malaysia
    Kelantan Darul Naim, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • Private Office 201
    Delagación Cuauhtemoc, DF 06700, Mexico
  • Hospital Civil de Guadalajara Fray Antonio Alcalde
    Guadalajara, Jalisco 44280, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo LEON CP 64460, Mexico
  • Hospital Angeles Culiacan
    Culiacan, Sinaloa 80020, Mexico
  • Instituto Biomedico de Investigacion A. C.
    Aguascalientes, 20127, Mexico
  • Indywidualna Specjalistyczna Praktyka Lekarska
    Gdansk, 80-266, Poland
  • Centrum Neurologii Klinicznej Sp. z o. o.
    Krakow, 31-505, Poland
  • Gabinet Lekarski A. Klimek
    Lodz, 90-148, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej IGNIS dr med. Alicja Lobinska
    Swidnik, 21-040, Poland
  • Epilepsy Control Institute
    San Juan, 00923, Puerto Rico
  • Spitalul Clinic de Urgenta "Prof. Dr. Nicolae Oblu"
    Iasi, Jud. Iasi 700309, Romania
  • Cabinet Medical Individual " Dr. Adina Maria Roceanu"
    Bucuresti, 010042, Romania
  • Municipal Healthcare Institution City Hospital #5, Neurology Department
    Barnaul, 656045, Russian Federation
  • State Medical Institution Republican Clinical Hospital
    Kazan, 420064, Russian Federation
  • Central Clinical Hospital #2 N.A. Semashko OAO RZD / Department of Rehabilitation
    Moscow, 107150, Russian Federation
  • Pyatigorsk City Hospital #2, Neurology Department,
    Pyatigorsk, 357538, Russian Federation
  • State Institution St. Petersburg Psychoneurological Research Institute V.M. Bekhterev of Roszdrav
    Saint-Petersburg, 192019, Russian Federation
  • Samara Regional Clinical Hospital M.I. Kalinin, Neurology and Neurosurgery Department
    Samara, 443095, Russian Federation
  • Institute for Mental Health
    Belgrade, 11 000, Serbia
  • National University Hospital
    Singapore, 119074, Singapore
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • Khon Kaen University, Faculty of Medicine, Neurology Unit, Department of Medicine
    Muang, Khon Kaen 40002, Thailand
  • Neurology Division, Department of Medicine, Pramongkutklao College of Medicine
    Bangkok, 10400, Thailand
09

References and documents

Publications

  • French J, Brandt C, Friedman D, Biton V, Knapp L, Pitman V, Chew M, Dubrava S, Posner HB. Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014 Aug;55(8):1220-8. doi: 10.1111/epi.12690. Epub 2014 Jun 24. PubMed 24962242 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Jul 2012, 17 months.

Results were first posted in Jun 2018, 5 years 10 months after primary completion. A results delay was requested in Sep 2013.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 17 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2010
First posted
Dec 17, 2010
StartActual
Feb 17, 2011
Primary completionActual
Jul 31, 2012
CompletionActual
Aug 1, 2012
Results delay requested
Sep 13, 2013
Results first posted
Jun 6, 2018
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01262677
Responsible party
Sponsor
First posted
Dec 17, 2010
Start date
Feb 17, 2011
Primary completion
Jul 31, 2012
Completion
Aug 1, 2012
Results posted
Jun 6, 2018
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion